



Markets
/
Stocks
/
nasdaq-mrk
/

Merck & Co Inc

MRK

View Detailed Chart

81.470USD

-4.900-5.67%

Close 04/04, 16:00（ET）Quotes delayed by 15 min

205.93BMarket Cap

12.03P/E TTM



Merck & Co Inc

81.470

-4.900-5.67%

Company

Intraday

30m

Today

-5.67%

5 Days

-8.68%

1 Month

-13.32%

6 Months

-25.78%

Year to Date

-18.10%

1 Year

-36.34%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 26 analysts

BUY

Current Rating

113.749

Target Price

39.62%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

150

Total

Median

Average

Company name

Ratings

Analysts

Merck & Co Inc

MRK

Biogen Inc

BIIB

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(10)

Neutral(0)

Buy(0)

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.905

Sell

RSI(14)

25.453

Sell

STOCH(KDJ)(9,3,3)

8.651

Oversold

ATR(14)

2.409

High Vlolatility

CCI(14)

-156.975

Sell

Williams %R

97.324

Oversold

TRIX(12,20)

-0.227

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

86.244

Sell

MA10

87.631

Sell

MA20

91.013

Sell

MA50

91.147

Sell

MA100

95.464

Sell

MA200

105.922

Sell

News

Merck & Co Inc reports results for the quarter ended December 31 - Earnings Summary

Merck & Co Inc MRK.N reported quarterly adjusted earnings of $1.72 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of sixteen analysts for the quarter was for earnings of $1.62 per share. Wall ...

ReutersTue, Feb 4

U.S. STOCKS ON THE MOVE-Merck & Co, Sirius XM Holdings, Palantir Technologies

Eikon search string for individual stock moves: The Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/3dKUyB8U.S. stock index futures were slightly lower on Tuesday as investors stayed away from risky assets after China deployed retaliatory tariffs...

ReutersTue, Feb 4

Company

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

Company codeMRK

CompanyMerck & Co Inc

CEOMr. Robert M. (Rob) Davis

Websitehttps://www.merck.com/